J-Ring M Tablet ER is a combination oral hypoglycemic agent containing Metformin 500 mg and Teneligliptin 20 mg, formulated for extended release to provide sustained glycemic control in patients with type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases endogenous incretin levels, thereby stimulating glucose-dependent insulin secretion and suppressing glucagon release. The extended-release formulation of J-Ring M Tablet ER ensures a gradual and consistent release of active ingredients, minimizing gastrointestinal side effects commonly associated with immediate-release metformin. This combination therapy is indicated for patients inadequately controlled on metformin alone or those requiring dual therapy to achieve optimal glycemic targets. The use of J-Ring M Tablet ER may improve HbA1c levels, fasting plasma glucose, and postprandial glucose while maintaining a favorable safety profile. It should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose. Contraindications include renal impairment, metabolic acidosis, and hypersensitivity to any component. Dose adjustments may be necessary based on renal function and clinical response.